Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions

Bibliography

• Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2011;285:1059-70
   Google Scholar
• Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8:21-9
   PubMed Web of Science ®Google Scholar
• Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxoid. Ann Rev Phramcol Toxicol 1986;26:427-53
   PubMed Web of Science ®Google Scholar
• Naumann M, Albanese A, Heinen F, et al. Safety and efficacy of botulinum toxin type A following long term use. Eur J Neurol 2006;13(Suppl 4):35-40
   PubMedGoogle Scholar
• Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared to type A. Neurology 1997;49:189-94
   PubMed Web of Science ®Google Scholar
• Chapple CR. Which preparation of botulinum toxin A should be used, where should it be injected, and how should its efficacy be assessed? Eur Urol 2012;61:936-8
   PubMed Web of Science ®Google Scholar
• Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 2004;61(Suppl 6):S5-10
   Google Scholar
• Apostolidis A. Pharmacotherapy for overactive bladder: minimally invasive treatment- botulinum toxins. Expert Opin Pharmacother 2011;12(7):1029-39
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson K-E, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol 2011;60:784-95
   PubMed Web of Science ®Google Scholar
• Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-8
   PubMed Web of Science ®Google Scholar
• Seth J, Khan MS, Dasgupta P, Sahai A. Botulinum toxin- What urologic uses does the data support? Curr Urol Rep 2013;14:227-34
   PubMedGoogle Scholar
• Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014;65:981-90
   PubMed Web of Science ®Google Scholar
• Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010;57:884-90
   PubMed Web of Science ®Google Scholar
• Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 2010;184:2578-85
   PubMed Web of Science ®Google Scholar
• Liu HT, Chancellor MB, Kuo HC. Urinary growth factor levels are elevated in patients with detrusor oveactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009;56:700-6
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Gasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:664-50
   Google Scholar
• Marino MJ, Terashima T, Steinauer JJ, et al. Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, amd pain behaviour. Pain 2014;155(4):674-84
   PubMed Web of Science ®Google Scholar
• Drinovac V, Bach-Rojecky L, Lackovic Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J Neural Transm 2014;121(6):665-9
   PubMed Web of Science ®Google Scholar
• Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn 2014;33:31-8
   PubMed Web of Science ®Google Scholar
• Luciani A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute and chronic inflammation. BJU Int 2008;101:336-70
   Google Scholar
• Coffield JA, Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther 2009;330(1):352-8
   PubMed Web of Science ®Google Scholar
• Lawrence GW, Ovsepian SV, Wang J, et al. Therapeutic effectiveness of botulinum neurotoxin A: potent blockade autonomic transmission by targeted cleavage of only the pertinent SNAP-25. Neuropharmacology 2013;70:287-95
   PubMed Web of Science ®Google Scholar
• Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342(9):665
   PubMed Web of Science ®Google Scholar
• Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010;183:2258-64
   PubMed Web of Science ®Google Scholar
• . Karsenty G, Denys P, Amarenco G, et al.Botulinum toxin A. Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2007;52:850-8
   PubMedGoogle Scholar
• Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus panel report. Eur Urol 2009;55:100-20
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol 2013;31:1469-74
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschon S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93
   PubMed Web of Science ®Google Scholar
• Tincello DG, Owen RK, Stack MC, Abrams KR. Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study. BJOG 2013;120:212-16
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo-controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Elovic E, Esquenazi A, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 2013;67:129-40
   Google Scholar
• Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007;178:1359-63
   PubMed Web of Science ®Google Scholar
• Karsenty G, Baverstock R, Carlson K, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract 2014;68(6):731-42
   PubMedGoogle Scholar
• Manecksha RP, Cullen IM, Ahmad S, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injections of abobotulinumtoxinA for refractory idiopathic overactive bladder. Eur Urol 2012;61(5):928-35
   PubMed Web of Science ®Google Scholar
• Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol 2010;7:661-7
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Le Gall N, Dasgupta P. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008;71:455-9
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008;15:407-15
   PubMed Web of Science ®Google Scholar
• Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519-27
   PubMed Web of Science ®Google Scholar
• Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (Botox) therapy in Germany. World J Urol 2010;28:385-90
   PubMed Web of Science ®Google Scholar
• Leong RK, Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011;108(4):558-64
   PubMed Web of Science ®Google Scholar
• Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscurinic refractory patients with overactive bladder/Urology. 2010;76(4):835-40
   Google Scholar
• Dysktra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139(5):919-22
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1707-14
   PubMed Web of Science ®Google Scholar
• Mahfouz W, Karsenty G, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update. Can J Urol 2011;18(4):5787-95
   PubMed Web of Science ®Google Scholar
• Kuo HC. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int J Clin Pract 2013;67(10):1044-9
   PubMed Web of Science ®Google Scholar
• Safari S, Jamali S, Habibollahi P, et al. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology 2010;76:225-30
   PubMed Web of Science ®Google Scholar
• Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord 2011;49(5):659-64
   PubMed Web of Science ®Google Scholar
• Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn 2008;27(8):793-6
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA. Treatment of detrusor sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71:24-6
   PubMed Web of Science ®Google Scholar
• Higgins JR, Gosling JA. Studies of the structure and intrinsic innervation of the normal human prostate. Prostate 1989;2:5-16
   PubMedGoogle Scholar
• Gkonos PJ, Krongard A, Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995;23:81-7
   PubMed Web of Science ®Google Scholar
• Chuang YC, Huang CC, Kang HY, et al. Novel action of botulinum toxin on the stroma and epithelial components of the prostate gland. J Urol 2006;175:1158-63
   PubMed Web of Science ®Google Scholar
• Marberger M, Chartier-Kastler E, Egerdie B, et al. A randomized double-blind placebo-controlled phase II dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 2013;63(3):496-503
   PubMed Web of Science ®Google Scholar
• de Kort LM, Kok ET, Jonges TN, et al. Urodynamic effects of transrectal intraprostatic onabotulinumtoxin A injections for symptomatic benign prostatic hyperplasia. Urology 2012;80(4):884-93
   Google Scholar
• Sacco E, Bientinesi R, Marangi F, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int 2012;110(11 Pt C):E837-44
   PubMedGoogle Scholar
• Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomised, placebo-controlled study. Urology 2003;62:259-65
   PubMed Web of Science ®Google Scholar
• Silva J, Silva C, Saraiva L, et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement: effect on prostate volume and micturition resumption. Eur Urol 2008;53:153-9
   PubMed Web of Science ®Google Scholar
• Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomised clinical trial. J Urol 2011;186:965-70
   PubMed Web of Science ®Google Scholar
• Kuo HC. Prostate botulinum A toxin injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670-4
   PubMed Web of Science ®Google Scholar
• Chuang YC, Chiang P, Yoshimura N, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006;98:1033-7
   PubMed Web of Science ®Google Scholar
• Silva J, Pinto R, Cavalho T, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 2011;107(12):1950-4
   PubMed Web of Science ®Google Scholar
• Offiah I, McMahon SB, O’Reilly BA. Interstitial cystitis/bladder pain syndrome: diagnosis and management. Int Urogynecol J 2013;24(8):1243-56
   PubMed Web of Science ®Google Scholar
• Bouchelouche K, Nording J. Recent developments in the management of interstitial cystitis. Curr Opin Urol 2003;13:309-13
   Web of Science ®Google Scholar
• Mayer R. Interstitial cystitis pathogenesis and treatment. Curr Opin Infect Dis 2007;20:77-82
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Oguchi T, Yokoyama H, et al. Bladder afferent hyperexcitability in bladder pain/interstitial cystitis. Int J Urol 2014;21(Suppl 1):18-25
   PubMed Web of Science ®Google Scholar
• Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol 2007;14:3599-607
   PubMedGoogle Scholar
• Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has anti-nociceptive effects in treating interstitial cystitis. Urology 2004;64:871-5
   PubMed Web of Science ®Google Scholar
• Russell A, Kavia R, Dasgupta P, Sahai A. The use of botulinum toxin for the treatment of urologic pain. Curr Opin Urol 2013;23(6):570-8
   PubMed Web of Science ®Google Scholar
• Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol 2013;189(2):548-56
   PubMed Web of Science ®Google Scholar
• Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinumtoxin A. Urology 2014;83(5):1030-4
   PubMed Web of Science ®Google Scholar
• Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/painful bladder syndrome. Int J Clin Pract 2013;67(5):427-34
   PubMed Web of Science ®Google Scholar
• Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2004;104:922-5
   PubMedGoogle Scholar
• El-Khawand D, Wehbe S, Whitmore K. Botulinum toxin for conditions of the female pelvis. Int Urogynecol J 2013;24(7):1073-81
   Web of Science ®Google Scholar
• Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginimus. Obstet Gynecol 2004;104:992-5
   Google Scholar
• Serefoglu EC, Silay MS. Botulinum toxin-A injection may be beneficial in the treatment of life-long premature ejaculation. Med Hypotheses 2010;74(1):83-4
   PubMed Web of Science ®Google Scholar
• Serefoglu EC, Hawley WR, Lasker GF, et al. Effect of botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats. J Sex Med 2014;11:1657-63
   PubMed Web of Science ®Google Scholar
• 2013. Available from: http://clinicaltrials.gov/show/NCT01917006 [Last accessed September 2014]
   Google Scholar
• Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, et al. Intravesical electromotive botulinum toxin type A administration – part II: clinical application. Urology 2011;77(2):439-45
   PubMedGoogle Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009;182(2):786-92
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT, Chuang YC, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-centre study. Eur Urol 2014;65(6):1117-24
   PubMed Web of Science ®Google Scholar
• Dolimbek BZ, Steward LE, Aoki KR, Atassi M. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin. Immunobiology 2011;216(6):698-706
   PubMed Web of Science ®Google Scholar